Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Inclusion Criteria: 1. Women aged from 18 to 70 years; 2. Histologically proven invasive unilateral breast cancer (regardless of the type); 3. Initial clinical condition compatible with complete initial resection; 4. No residual macro or microscopic tumor after surgical excision; 5. Beginning of chemotherapeutic treatment no later than day 42 after the initial surgery; 6. positive lymph node or negative lymph node with tumor size \> 1.0cm 7. Patient presenting one of the following criteria (reviewed before randomization by referent pathologist): Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER\<1%, PR\<1% (IHC), HER2 negativity is defined as IHC 0-1+, or \[IHC 2+ and FISH or CISH negative\]. 8. No clinically or radiologically detectable metastases (M0); 9. No peripheral neuropathy \> 1; 10. WHO Performance status (ECOG) of 0 or 1; 11. Adequate recovery from recent surgery (at least one week must have elapsed from the time of a minor surgery (excluding breast biopsy); at least three weeks for major surgery); 12. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin \> 9 g/dl); 13. Adequate hepatic function: ASAT and ALAT ≤ 3 ULN alkaline phosphatases ≤ 2.5 ULN,total bilirubin ≤ 1,5 ULN; 14. Adequate renal function: serum creatinine ≤ 1 ULN; 15. Patients accepting contraception intake during the overall length of treatment if of childbearing potential; 16. Adequate cardiac function, LEVF value \> 50% by Muga scan or echocardiography; 17. Signed written informed consent. Exclusion Criteria: 1. Bilateral breast cancer or patient with controlateral DCIS; 2. Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type; 3. Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer); 4. ER+ or PR+ or Her-2 overexpression 5. Any clinically or radiologically suspect and non-explored damage to the controlateral breast; 6. Any chemotherapy, hormonal therapy or radiotherapy before surgery; 7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral ephitelioma) in the preceding 5 years, including invasive controlateral breast cancer; 8. Patients already included in another therapeutic trial involving an experimental drug; 9. Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study; 10. LEVF \< 50% (MUGA scan or echocardiography); 11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (\>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to randomization; 12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL; 13. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 8 weeks after treatment completion; 14. Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase; 15. Women with a positive pregnancy test en enrollment or prior to study drug administration; 16. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial; 17. Individual deprived of liberty or placed under the authority of a tutor.